Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Hui Zheng, Shi-Qi Fan, Yun-Zhou Shi, Jing-Tao Liang & Xin-Yu Xiao. (2023) Matching adjusted indirect comparison of acupuncture versus fremanezumab in the preventive treatment of episodic migraine. Current Medical Research and Opinion 39:3, pages 409-416.
Read now
Read now
Bogdan Muresan, Carla Mamolo, Joseph C. Cappelleri, Eric Leip, Andrea Viqueira & Bart Heeg. (2021) An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion 37:5, pages 801-809.
Read now
Read now
Karen Reckamp, Huamao M. Lin, Joice Huang, Irina Proskorovsky, William Reichmann, Stanimira Krotneva, David Kerstein, Hui Huang & Joseph Lee. (2019) Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Current Medical Research and Opinion 35:4, pages 569-576.
Read now
Read now
Moshe Yair Levy, Lisa J. McGarry, Hui Huang, Stephanie Lustgarten, Silvia Chiroli & Sergio Iannazzo. (2019) Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison. Current Medical Research and Opinion 35:3, pages 479-487.
Read now
Read now
Junlong Li, Stefanie Knoll, Iryna Bocharova, Wenxi Tang & James Signorovitch. (2019) Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. Current Medical Research and Opinion 35:1, pages 105-111.
Read now
Read now
Robert J. Fox, Andrew Chan, Annie Zhang, James Xiao, Dane Levison, James B. Lewin, Michael R. Edwards & Jing L. Marantz. (2017) Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Current Medical Research and Opinion 33:2, pages 175-183.
Read now
Read now
Dominick Latremouille-Viau, Annie Guerin, Roy Nitulescu, Patrick S. Gagnon, George J. Joseph & Lei Chen. (2017) Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. Journal of Medical Economics 20:1, pages 63-71.
Read now
Read now
Jennifer Whiteley, Shrividya Iyer, Sean D. Candrilli & James A. Kaye. (2015) Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea. Current Medical Research and Opinion 31:2, pages 299-314.
Read now
Read now
James E. Signorovitch, Keith A. Betts, William M. Reichmann, Darren Thomason, Phil Galebach, Eric Q. Wu, Lei Chen & Daniel J. DeAngelo. (2015) One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Current Medical Research and Opinion 31:2, pages 315-322.
Read now
Read now
Roxanne Ferdinand, Stephen A Mitchell, Sarah Batson & Indra Tumur. (2012) Treatments for chronic myeloid leukemia: a qualitative systematic review. Journal of Blood Medicine 3, pages 51-76.
Read now
Read now
Ramon Tiu & Matt Kalaycio. (2012) Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons. Leukemia & Lymphoma 53:7, pages 1263-1272.
Read now
Read now
Articles from other publishers (32)
Owen Cassidy, Marie Harte, Lea Trela-Larsen, Cathal Walsh, Arthur White, Laura McCullagh & Joy Leahy. (2023) A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons. Value in Health 26:11, pages 1665-1674.
Crossref
Crossref
Tanja Proctor, Samuel Zimmermann, Svenja Seide & Meinhard Kieser. (2022) A comparison of methods for enriching network meta‐analyses in the absence of individual patient data. Research Synthesis Methods 13:6, pages 745-759.
Crossref
Crossref
Mustafa Hashmi, Jeremy Rassen & Sebastian Schneeweiss. (2021) Single-arm oncology trials and the nature of external controls arms. Journal of Comparative Effectiveness Research 10:12, pages 1053-1066.
Crossref
Crossref
Venediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, K. Jack Ishak, Hemant Phatak, Ting Yu & Murtuza Bharmal. (2021) How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments. Value in Health 24:8, pages 1137-1144.
Crossref
Crossref
Lauren Cappiello, Zhiwei Zhang, Changyu Shen, Neel M. Butala, Xinping Cui & Robert W. Yeh. (2021) Adjusting for Population Differences Using Machine Learning Methods. Journal of the Royal Statistical Society Series C: Applied Statistics 70:3, pages 750-769.
Crossref
Crossref
Venediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, K. Jack Ishak, Hemant Phatak, Mairead Kearney, John W. Stevens, Agnes Benedict & Murtuza Bharmal. (2019) Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. PharmacoEconomics 37:12, pages 1537-1551.
Crossref
Crossref
Xianbin Tian, Hefei Zhang, Tycho Heimbach, Handan He, Aby Buchbinder, Mary Aghoghovbia & Florence Hourcade‐Potelleret. (2018) Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor. The Journal of Clinical Pharmacology 58:12, pages 1533-1540.
Crossref
Crossref
John W. Stevens, Christine Fletcher, Gerald Downey & Anthea Sutton. (2018) A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. Research Synthesis Methods 9:2, pages 148-162.
Crossref
Crossref
Patricia K. Coyle, Shulian Shang, Zhen Xiao, Qunming Dong & Carmen Castrillo-Viguera. (2018) Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week. Multiple Sclerosis and Related Disorders 22, pages 134-138.
Crossref
Crossref
David M. PhillippoAnthony E. AdesSofia DiasStephen PalmerKeith R. AbramsNicky J. Welton. (2017) Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Medical Decision Making 38:2, pages 200-211.
Crossref
Crossref
Jason Shafrin, Anshu Shrestha, Amitabh Chandra, M. Haim Erder & Vanja Sikirica. (2017) Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder. Health Economics 26:11, pages 1459-1466.
Crossref
Crossref
Andrew Chan, Gary Cutter, Robert J Fox, James Xiao, James B Lewin & Michael R Edwards. (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research 6:4, pages 313-323.
Crossref
Crossref
Istvan Majer, Gijs van de Wetering, Zoltan Polanyi, Arun Krishna, Elisabeth Gray & Anuja Roy. (2016) Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. Applied Health Economics and Health Policy 15:1, pages 45-55.
Crossref
Crossref
Areti Angeliki Veroniki, Sharon E. Straus, Charlene Soobiah, Meghan J. Elliott & Andrea C. Tricco. (2016) A scoping review of indirect comparison methods and applications using individual patient data. BMC Medical Research Methodology 16:1.
Crossref
Crossref
Koichi Takahashi, Hagop M. Kantarjian, Yulong Yang, Koji Sasaki, Preetesh Jain, Sara DellaSala, Farhad Ravandi, Tapan Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Elias Jabbour & Jorge E. Cortes. (2016) A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122:21, pages 3336-3343.
Crossref
Crossref
Daniel Shao-Weng Tan, António Araújo, Jie Zhang, James Signorovitch, Zheng-Yi Zhou, Xiaopeng Cai & Geoffrey Liu. (2016) Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. Journal of Thoracic Oncology 11:9, pages 1550-1557.
Crossref
Crossref
Zhiwei ZhangLei NieGuoxing SoonZonghui Hu. (2016) New methods for treatment effect calibration, with applications to non-inferiority trials. Biometrics 72:1, pages 20-29.
Crossref
Crossref
Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez & Anuraag Kansal. (2014) Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches. PharmacoEconomics 32:6, pages 559-572.
Crossref
Crossref
Françoise Huguet. (2014) ENESTnd trial: a Phase III study comparing nilotinib with imatinib as front-line therapy of early chronic-phase chronic myeloid leukemia. International Journal of Hematologic Oncology 3:2, pages 117-129.
Crossref
Crossref
James Signorovitch, Rajeev Ayyagari, William M. Reichmann, Eric Q. Wu & Lei Chen. (2014) Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis. Cancer Treatment Reviews 40:2, pages 285-292.
Crossref
Crossref
Emmanuel Giménez García, M. Angeles Portero, Concepción Boqué, Asunción Echeveste, Raquel de Paz, Santiago del Castillo, Reyes Calzada, Juan Diego González & Valentín García-Gutiérrez. (2014) Análisis del impacto presupuestario tras la comercialización de nilotinib en el tratamiento de primera línea en pacientes con leucemia mieloide crónica de nuevo diagnóstico en España. PharmacoEconomics Spanish Research Articles 11:1, pages 5-14.
Crossref
Crossref
Stuart Mealing, Leticia Barcena, Neil Hawkins, James Clark, Victoria Eaton, Ishan Hirji & Catherine Davis. (2013) The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Experimental Hematology & Oncology 2:1.
Crossref
Crossref
James Signorovitch, Elyse Swallow, Evan Kantor, Xufang Wang, Judith Klimovsky, Tomas Haas, Beth Devine & Peter Metrakos. (2013) Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Experimental Hematology & Oncology 2:1.
Crossref
Crossref
Elias Jabbour & Jeffrey H. Lipton. (2013) A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma Myeloma and Leukemia 13:6, pages 646-656.
Crossref
Crossref
Lei Nie, Zhiwei Zhang, Daniel Rubin & Jianxiong Chu. (2013) Likelihood reweighting methods to reduce potential bias in noninferiority trials which rely on historical data to make inference. The Annals of Applied Statistics 7:3.
Crossref
Crossref
유기연. (2013) The Effect of Treatment for Chronic Myeloid Leukemia: Meta- Analysis. Journal of Korean Society of Health-System Pharmacists 30:4, pages 304-319.
Crossref
Crossref
Mirjana Pavlovic & Bela BalintMirjana Pavlovic & Bela Balint. 2013. Stem Cells and Tissue Engineering. Stem Cells and Tissue Engineering
33
52
.
M. Haim Erder, Jipan Xie, James E. Signorovitch, Kristina S. Chen, Paul Hodgkins, Mei Lu, Eric Q. Wu & Vanja Sikirica. (2012) Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder. Applied Health Economics and Health Policy 10:6, pages 381-395.
Crossref
Crossref
Robert Mah. 2012. Bioactive Heterocyclic Compound Classes. Bioactive Heterocyclic Compound Classes
255
273
.
James E. Signorovitch, Vanja Sikirica, M. Haim Erder, Jipan Xie, Mei Lu, Paul S. Hodgkins, Keith A. Betts & Eric Q. Wu. (2012) Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. Value in Health 15:6, pages 940-947.
Crossref
Crossref
Susanne Saussele & Markus Pfirrmann. (2012) Clinical Trials in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 7:2, pages 109-115.
Crossref
Crossref
David W. Woessner, Carol S. Lim & Michael W. Deininger. (2011) Development of an Effective Therapy for Chronic Myelogenous Leukemia. The Cancer Journal 17:6, pages 477-486.
Crossref
Crossref